How Will Covid-19 Pill Works?

My Geek Score: According to the maker of the drug Pfizer, an experimental antiviral pill appears to work very well in preventing people at high risk of severe COVID19 from being hospitalized and dying, in the prevention of hospitalization or death in patients with COVID19 who were at high risk of serious complications. The company has announced plans to seek FDA clearance for emergency use of the drug. The drug appears to be working so well that Pfizer has stopped enrolling in the trial of the drug, which works by blocking an enzyme called protease that the new coronavirus needs to reproduce further. Stopping a clinical trial is a rare action that is usually taken when a therapy appears to be very effective or clearly unsafe. in either case, it is considered unethical to continue a clinical trial in which people are randomly assigned an active drug or a placebo when safer or more effective options are available in that case. the company said in a statement. recommended by an independent group of consultants overseeing the study, called the Data Safety Oversight Committee, and conducted in consultation with the FDA. “These data suggest that our oral antiviral candidate if approved or cleared by regulatory authorities has the potential to save patient lives, reduce the severity of COVID19 infections, and eliminate up to nine hospitalizations on ten. In a clinical trial that included more than 1,900 patients who tested positive for COVID19 and were at risk for serious complications from their infections, those who received Paxlovid within 3 days of onset of symptoms were 89% less likely to be hospitalized compared to those who received a placebo pill three of 389 patients who received the drug were hospitalized, compared with 27 of 385 who received a placebo. At the onset of symptoms, six of 607 were hospitalized within 28 days, compared with 41 of 612 who received a placebo. There were no deaths within one month in the patients who took Paxlovid, but 10 deaths in the group that received the placebo. The news comes following an announcement last month by pharmaceutical company Merck that its investigational antiviral pill, molnupiravir, reduced the risk of hospitalization or death in patients with mild to moderate COVID Pill by 50%, compared to a placebo became the first country to allow the use of molnupiravir, which is branded by Lagevrio. Stephen Griffin, Ph.D., associate professor of medicine at Leeds University, praised the success of the two new antiviral pills. "Both show that with the proper investment, the development of direct-acting antiviral drugs targeting SARSCoV2 was eminently feasible and ultimately proved to be much more effective than reuse of other drugs with questionable antiviral effects," Griffin said. , which was not involved in the development of nor drug.

https://bit.ly/mygeekscore

images.google.com.pe/url?sa=t&url=https%3A%2F%2Fwww.mygeekscore.com

www.google.com.pe/url?sa=t&url=https%3A%2F%2Fwww.mygeekscore.com